Consensus Gilead Sciences, Inc. Sao Paulo

Stocks

GILD34

BRGILDBDR000

Pharmaceuticals

Delayed Sao Paulo 13:22:49 2026-09-15 EDT			5-day change	1st Jan Change
62.65 ^BRL	+2.65%		+1.08%	+9.28%

01:05pm	Gilead Sciences, Inc. and Pan American Health Organization Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean	CI
11:50am	Gilead Sciences, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 10:45 AM

6ce3cda.Rp9KMTCvP9qBw6pdGsHmxR5HqiUKPphXzgU0jT727rM.MKwEWV7AVZzrt-4JX7eUn1UewEt7Ce0zjEdu92msqcQg5gEGX_Ba4syJng~ce5ebf0f90c1782a979d0ad5b6082585

Analysts' recommendations: Gilead Sciences, Inc.

09-10	HSBC Adjusts Price Target on Gilead Sciences to $175 From $155, Keeps Buy Rating	MT
08-05	Gilead Sciences Delivers 'Plenty' to Like in Q2, RBC Says	MT
08-05	Leerink Partners Adjusts Price Target on Gilead Sciences to $130 From $126	MT
08-05	Goldman Sachs Adjusts Price Target on Gilead Sciences to $135 From $130	MT
08-05	RBC Capital Adjusts Gilead Sciences Price Target to $123 From $120, Maintains Sector Perform Rating	MT
08-04	Merck's Weekly HIV Treatment Pipeline 'Interesting,' UBS Says	MT
07-28	Barclays Adjusts Gilead Sciences Price Target to $145 From $155, Maintains Equalweight Rating	MT
07-23	Leerink Partners Adjusts Gilead Sciences Price Target to $126 From $127, Maintains Market Perform Rating	MT
07-21	Gilead Sciences Shares Fall After Downgrade From Leerink Partners	MT
07-21	Analyst recommendations: Gilead, Salesforce, Goldman Sachs, Carvana, Crowdstrike…
07-21	Leerink Partners Downgrades Gilead Sciences to Market Perform From Outperform, Adjusts PT to $127 From $146	MT
07-08	Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says	MT
07-08	Morgan Stanley Adjusts Price Target Gilead Sciences to $166 From $168, Maintains Overweight Rating	MT
07-07	Truist Securities Adjusts Gilead Sciences Price Target to $156 From $157	MT
07-07	RBC Capital Adjusts Gilead Sciences Price Target to $120 From $122, Maintains Sector Perform Rating	MT
07-06	Analyst recommendations: Chubb, Delta Air Lines, Pfizer, AMD, Dow…
07-06	HSBC Upgrades Gilead Sciences to Buy From Hold, Adjusts Price Target to $155 From $133	MT
06-08	Gilead Sciences Faces Potential Threat From In Vivo CAR-T, RBC Says	MT
05-20	Maxim Upgrades Gilead Sciences to Buy From Hold, Price Target is $165	MT
05-19	Daiwa Securities Adjusts PT on Gilead Sciences to $150 From $161, Maintains Outperform Rating	MT
05-11	Gilead's Emvistegrast Readout Unlikely to Move Stock, RBC Says	MT
05-11	Rothschild & Co Redburn Adjusts Price Target on Gilead Sciences to $167 From $170	MT
05-08	Leerink Partners Adjusts Price Target on Gilead Sciences to $146 From $148	MT
05-08	Gilead Sciences' Increased Yeztugo Guidance is 'Good Enough' for the Stock, Morgan Stanley Says	MT
05-08	Morgan Stanley Adjusts Price Target on Gilead Sciences to $168 From $175	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ELI LILLY AND COMPANY					+15.85%
	JOHNSON & JOHNSON					+4.35%
	ABBVIE INC.					+6.43%
	ROCHE HOLDING AG					+3.41%
	NOVARTIS AG					+10.07%
	ASTRAZENECA PLC					+29.47%
	AMGEN INC.					+1.71%
	NOVO NORDISK A/S					+10.62%
	GILEAD SCIENCES, INC.					+8.02%
	Average					+9.99%
	Weighted average by Cap.					+10.38%